Table 1 Patients demographics between ranibizumab and bevacizumab groups
Parameters | Ranibizumab | Bevacizumab | P value* |
|---|---|---|---|
Number | 22 patients 23 eyes | 42 patients 43 eyes | |
Age (years) | 50.48 ± 12.38 | 55.70 ± 12.78 | 0.12 |
Gender (male:female) | 3:19 | 13:29 | 0.09 |
Laterality (right:left) | 16:7 | 24:19 | 0.28 |
Refraction (diopter) | -12.34 ± 5.05 | -14.85 ± 6.21 | 0.32 |
Axial length (mm) | 30.28 ± 1.32 | 30.45 ± 1.51 | 0.87 |
Follow-up period (month) | 22.87 ± 9.10 | 22.44 ± 9.41 | 0.86 |
Lens status | 0.76 | ||
Phakia | 16 | 25 | |
Pseudophakia or aphakia | 7 | 18 | |
BCVA (logMAR) | 0.63 ± 0.30 | 0.67 ± 0.28 | 0.59 |
Location of CNV | 0.71 | ||
Subfoveal | 15 (65%) | 30 (70%) | |
Juxtafoveal | 8 (35%) | 13 (30%) | |
CFT (μm) | 304 ± 73 | 287 ± 71 | 0.40 |